showed little single agent activity unless combined with a chemotherapeutic agent 76 (Merino et al., 2017) . Co-dosing Bcl-xL and MCL1 inhibitors to achieve effective 77 treatment may be complicated by severe accompanying side effects. 
91
it is imperative to uncover additional targets that may sensitize cells to these treatments.
93
We reasoned that a genome wide search could uncover new targets that modulate the 94 therapeutic activity of CDK9i and MCL1i and suggest combination therapies to 95 resensitize tumor cells to these anti-cancer drugs. As lung cancer is the leading cause of 96 cancer mortality and most NSCLC patients develop resistance to first-line treatment, we 97 performed genome-wide CRISPR inhibition (CRISPRi) screens in a NSCLC line resistant 98 to both CDK9 and MCL1 inhibition (Siegel, Miller, & Jemal, 2016) . We discovered that 
108
We assessed a panel of NSCLC lines for their sensitivity to CDK9i (AZD5576) or MCL1i
109
(AZD5991) currently in clinical trials ( Figure 1B and Table S1 ). Several cell lines with 110 amplified MCL1 (copy number ≥ 3) rely on overexpression of MCL1 to escape apoptosis 111 and were highly sensitive to CDK9i and MCL1i. We also found several NSCLC lines that 112 remained resistant to CDK9i and MCL1i despite being MCL1-amplified. We examined 
134
Preclinical studies suggest dual inhibition of MCL1 and Bcl-xL may not be a clinically 135 viable option due to the highly toxic side effects. We therefore sought to identify alternate 
138
and transduce easily, making them an optimal cell line for a functional genomics screen.
139
Because prolonged CDK9i treatment induces non-specific cell death, a typical growth-140 based screen that measures cell abundance after 14 to 21 days of compound exposure 141 was inappropriate. Instead, we designed a positive selection FACS-based screen for 142 apoptosis that could finish within 6 hours (the optimal treatment window to maximize on-
143
target cell death and minimize non-specific cell death). We designed the screen to 
148
We generated a clonal LK2 CRISPRi cell line to ensure uniform expression of dCas9- 
244
Using two independent stable LK2 CRISPRi lines targeting CUL5, RNF7, UBE2F or Bcl-245 xL, we validated that individual knockdowns of these genes followed by treatment with 
289
In an attempt to find the CRL5 substrate adaptor responsible for resensitization to MCL1 Figure S3D ). We also confirmed by western blotting that depletion of CUL5 had no 310 effect on MCL1 and Bcl-xL levels ( Figure S3E ).
312
Since p53 levels were not directly affected by loss of CRL5, we hypothesized that CRL5 
867
Average of 2 independent experiments is graphed. Green highlighted points indicate 868 genes with a known role in apoptosis that had a significant fold change over background.
869
Magenta points highlight members of the CUL5-RNF7-UBE2F ubiquitin complex that 
888
Cell Event. Error bars are standard deviations of three independent biological replicates. 
959
Error bars are standard deviations of three biological replicates.
960
(B) Western blotting validating loss of CUL5 and UBE2F protein in the three CUL5-KO
961
clones and one UBE2F-KO clone respectively. As shown before, protein levels of RNF7
962
are also reduced when CUL5 is absent. GAPDH, loading control.
963
(C) Sanger sequencing traces of the alleles generated in the CUL5-and UBE2F
964
knockouts. Exon 1 size is indicated, and resulting deletions are shown.
965
(D) CUL5-KO and UBE2F-KO clones were treated with 3μM CDK9i for 6 hours or 1μM
966
MCL1i for 12 hours. Percent apoptosis determined using Cell Event detection by flow Figure S1 ). MAGeCK: sgRNA summary for CDK9i.
1036
Table S6 (related to Figure S1 ). MAGeCK: gene summary for CDK9i.
1037
CDK9i treatment condition compared to 'background'. Ordered by top enriched genes.
1039
Table S7 (related to Figure S1 ). MAGeCK: sgRNA summary for MCL1i.
1041
Table S8 (related to Figure S1 ). MAGeCK: sgRNA summary for MCL1i.
1042
MCL1i treatment condition compared to background. Ordered by top enriched genes.
1044
Table S9 (related to Figure S4 ). Analysis of apoptosis following knockdown of 1045 putative CUL5 substrate adaptors challenged with CDK9i or MCL1i.
1047
Table S10 (related to Figure 3 and S3) . Protospacer sequences.
1048 1049 Table S11 . Primer Sequences
